Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsCNTX -0.95%24 14-Day RSI is 32.23 as of Jul. 29, 2026. GuruFocus rates CNTX with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, Context Therapeutics ranks better than 88.88% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Context Therapeutics 14-Day RSI Related Terms
CNTX vs INKT, XLO, BOLD: 14-Day RSI Comparison
For the Biotechnology subindustry, Context Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Context Therapeutics (CNTX) has a 14-Day RSI of 32.23 as of Jul. 29, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Context Therapeutics and its competitors. According to the industry distribution chart, Context Therapeutics ranks #158 out of 1421 companies in the Biotechnology industry, placing it in the top 11.1%.
Is Context Therapeutics' 14-Day RSI too high?
Context Therapeutics' current 14-Day RSI is 32.23. The Biotechnology industry median 14-Day RSI is 43.76. Context Therapeutics' value of 32.23 is 26.3% below this industry median. Based on the distribution chart, Context Therapeutics ranks #158 out of 1421 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Context Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' 14-Day RSI compare to INKT and XLO?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #158 out of 1421 companies for 14-Day RSI. This places Context Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 43.76. Context Therapeutics' value of 32.23 is 26.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 43.76, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Context Therapeutics's current 14-Day RSI of 32.23 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Context Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 43.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Context Therapeutics's current 14-Day RSI is 32.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (CNTX) has a current 14-Day RSI of 32.23. The current 14-Day RSI is 32.23 and 26.3% below the Biotechnology industry median of 43.76. Context Therapeutics' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Context Therapeutics (CNTX), the current 14-Day RSI is 32.23 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
24GF Score
Get the complete analysis for CNTX
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTX has been successfully added to your 
